Legend Biotech Corp (LEGN) Debt to Equity (2021 - 2024)
Legend Biotech (LEGN) has disclosed Debt to Equity for 4 consecutive years, with $0.29 as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Debt to Equity rose 28.75% year-over-year to $0.29, compared with a TTM value of $0.29 through Dec 2024, up 28.75%, and an annual FY2024 reading of $0.29, up 28.75% over the prior year.
- Debt to Equity was $0.29 for Q4 2024 at Legend Biotech, up from $0.22 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.35 in Q4 2022 and bottomed at $0.16 in Q4 2021.
- Average Debt to Equity over 4 years is $0.26, with a median of $0.26 recorded in 2023.
- The sharpest move saw Debt to Equity surged 122.9% in 2022, then plummeted 35.87% in 2023.
- Year by year, Debt to Equity stood at $0.16 in 2021, then soared by 122.9% to $0.35 in 2022, then tumbled by 35.87% to $0.22 in 2023, then grew by 28.75% to $0.29 in 2024.
- Business Quant data shows Debt to Equity for LEGN at $0.29 in Q4 2024, $0.22 in Q4 2023, and $0.35 in Q4 2022.